Description
Product Description
Saralasin is a synthetic peptide analog of angiotensin II, modified to act as a competitive antagonist at angiotensin II receptors. Supplied as the trifluoroacetate (TFA) salt in lyophilized powder form, Saralasin is intended strictly for research and laboratory use.
Historically, Saralasin has played an important role in cardiovascular and endocrine research, particularly in studies of the renin–angiotensin–aldosterone system (RAAS). In experimental models, it is used to investigate angiotensin II–mediated vasoconstriction, blood pressure regulation, receptor binding dynamics, and hormone signaling pathways. Its well-characterized pharmacological profile makes it a classical reference compound in angiotensin receptor research.
Product Specifications
| Item | Description |
|---|---|
| Product Name | Saralasin |
| Synonyms | Saralasin Acetate, Angiotensin II Antagonist |
| CAS Number | 34273-10-4 |
| Molecular Formula | C50H71N13O12 (peptide, approximate) |
| Molecular Weight | ~912.1 g/mol |
| Amino Acid Sequence | Sar¹-Ala⁸-Angiotensin II |
| Peptide Type | Synthetic angiotensin II analog peptide |
| Form | Lyophilized powder (TFA salt) |
| Purity | ≥98% (HPLC) |
| Strength Options | 1 mg / 5 mg / 10 mg |
| Appearance | White to off-white powder |
| Identity Verification | HPLC, Mass Spectrometry |
| Solubility | Soluble in water or aqueous buffers |
| Packaging | Sterile, sealed research vials |
| Storage Condition | −20 °C, dry and light-protected |
| Intended Use | Research use only (RUO) |
Applications
Saralasin is commonly used in the following research areas:
Renin–angiotensin–aldosterone system (RAAS) studies
Angiotensin II receptor binding and antagonism research
Cardiovascular physiology and blood pressure regulation models
Endocrine signaling and hormone interaction studies
Pharmacological comparison of angiotensin receptor modulators
- PubMed – Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension

saralasin tfa Chemical structure
Usage & Reconstitution
Saralasin (TFA) lyophilized powder should be handled using standard sterile laboratory techniques. Reconstitution is typically performed in sterile water or suitable aqueous buffers to prepare stock solutions for experimental use.
Aliquoting after reconstitution is recommended to avoid repeated freeze–thaw cycles. Final working concentrations should be optimized according to receptor assays and model systems.
Storage & Stability
Store unopened vials at −20 °C
Protect from moisture and light
Avoid repeated freeze–thaw cycles after reconstitution
Properly stored aliquots remain stable for extended research use
Shipping Guarantee
Saralasin (TFA) lyophilized powder is packaged according to standardized laboratory material handling procedures:
Moisture- and light-protected inner packaging
Secure outer containers for transit protection
Batch-level labeling for traceability
Cold-chain handling applied when required
Contact & Bulk Inquiry
For inquiries regarding Saralasin (TFA) high-purity lyophilized powder, including bulk supply, specifications, and research support, please contact our team through the inquiry form or designated communication channels.
Our team can assist with:
Bulk and wholesale supply options
Available specifications and batch consistency
Technical documentation requests (COA, HPLC, MS)
International shipping and logistics coordination
Disclaimer
This product is intended for research and laboratory use only.
Not for human or veterinary use.
All handling and experimental applications must comply with applicable laws and institutional regulations.



Reviews
There are no reviews yet.